Scinai Immunotherapeutics (SCNI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significant bank loan into equity to secure its Nasdaq listing compliance, expected by August 23, 2024. The company also reported confidence in their contract development and manufacturing organization (CDMO) services, with projected sales growth following positive market engagement and development milestones in its pipeline, including promising results for a psoriasis treatment and strategic partnership pursuits for its NanoAb therapies.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.